BOSTON SCIENTIFIC CORP

BSX

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001225208-26-003177
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Smith Cathy R (Director)

Summary

Type

Neutral

Net shares

0

% of shares

0.00%

Amount (USD)

$0

Insider confidence score

52.5 out of 100

Positive

  • Minimal sell amount (<$10K)

Derivative Transactions

Transaction 1

Security

Deferred Stock Units

Action

Grant

Date

2026-03-02

Code

A

Net shares

+556.0

Acquired/Disposed

Acquired

Shares Owned Before

0.0

Shares Owned After

556.0

Transaction 2

Security

Deferred Stock Units

Action

Grant

Date

2026-03-02

Code

A

Net shares

+323.0

Acquired/Disposed

Acquired

Shares Owned Before

556.0

Shares Owned After

879.0

Filing's footnotes

1. Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Grant of deferred stock units to non-employee director following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $42,419.50 (representing 100% of the prorated amount of the non-employee director compensation program's annual equity award having a value of $215,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

3. Grant of deferred stock units in lieu of 100% yearly cash compensation following initial appointment to the Board of Directors, which, pursuant to the Company's non-employee director compensation program, has been prorated for the time period from the effective date of the appointment to the date of the Company's 2026 annual meeting of stockholders. The grant of deferred stock units vests in full upon the next annual meeting of stockholders. Reflects a value of approximately $24,662.50 (representing 100% of the prorated amount of the non-employee director compensation program's cash retainer having a value of $125,000) divided by the closing price of the common stock on the date of grant. Vested shares will be issued to the reporting person following the reporting person's separation from Board of Director service, in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.